



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Chawla et al.

Serial No.: 10/511,486

Examiner: TBA

Filing Date: October 15, 2004

Group Art Unit: TBA


Title: METHOD OF STABILIZING BUPROPION HYDROCHLORIDE TABLETS

CERTIFICATE OF MAILING

I certify that the following correspondence:

- Transmittal of Information Disclosure Statement
- Information Disclosure Citation
- Copies of cited references
- Postcard

is being deposited on May 27, 2005 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Box 313(b) Washington, D.C. 20231.


Kim Campbell

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-249US

In Re Application Of: CHAWLA et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/511,486	October 15, 2004	TBA	TBA	TBA	TBA

Title: METHOD OF STABILIZING BUPROPION HYDROCHLORIDE TABLETS

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-249US

In Re Application: **CHAWLA et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/511,486	October 15, 2004	TBA	TBA	TBA	TBA

Title: **METHOD OF STABILIZING BUPROPION HYDROCHLORIDE TABLETS**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. **50-0912** as described below.
- Charge the amount of _____
 Credit any overpayment.
 Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

William D. Hare

Signature

*This certificate may only be used if paying by deposit account.

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

May 27, 2005
(Date)

Kim Campbell

Signature of Person Mailing Correspondence

Kim Campbell

Typed or Printed Name of Person Mailing Certificate

Dated: May 27, 2005

William D. Hare, Esq.
Reg. No. 44,739
Ranbaxy Inc.
600 College Road East
Suite 2100
Princeton, NJ 08540
Telephone: 609-720-5378
Facsimile

CC:

INFORMATION DISCLOSURE CITATION

Docket No.: RLL-119US

Serial No.: 10/511,486

Applicants: CHAWLA *et al.*

Filed: 10/15/2004

Group:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	5,358,970	10/25/1994	Ruff <i>et al.</i>	514	649	
	A2	5,427,798	6/27/1995	Ludwig <i>et al.</i>	424	464	
	A3	5,541,231	7/30/1996	Ruff <i>et al.</i>	514	649	
	A4	5,731,000	3/24/1998	Ruff <i>et al.</i>	424	451	
	A5	5,763,493	6/9/1998	Ruff <i>et al.</i>	514	617	
	A6	5,968,553	10/19/1999	Maitra <i>et al.</i>	424	474	
	A7	6,033,686	3/7/2000	Seth	424	482	
	A8	6,238,697	5/29/2001	Kumar <i>et al.</i>	424	464	
	A9	6,242,496	6/5/2001	Kulkarni <i>et al.</i>	514	649	
	A10	6,306,436	10/23/2001	Chungi <i>et al.</i>	424	464	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	B1	EP 1 020 184	7/19/2000	EPO	A61K	31/135	
	B2	EP 1 275 383	1/15/2003	EPO	A61K	31/135	

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.